Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study

ConclusionsTolvaptan seemed to have no definitive effect on reducing ascites; however, it might be effective in at least some cancer patients. No new safety concerns were identified at doses of 3.75 –30 mg/day.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research